Brind.

Amgen and Gilead Sciences Compared on Dividend Yields and Valuation

1 report, 1 independent Updated Sun 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A comparison of Amgen and Gilead Sciences noted that both companies offer attractive dividends within the biotech sector. Amgen has a forward dividend yield exceeding 2.2%, while Gilead Sciences' yield is slightly below 2.1%. Gilead Sciences reported a dividend payout ratio of 43.5%, compared to Amgen's 60.9%, and trades at a forward earnings multiple of 15.6 times versus Amgen's 16.7 times.

From fool.com

Why it matters

Some supportBrind's analysis of the reports

The comparison of financial metrics, including dividend yield and payout ratio, provides investors with different perspectives on the long-term investment viability of both companies. These factors influence how investors evaluate the relative financial health and income potential of Amgen and Gilead Sciences.

From fool.com

Who's involved

  • AmgenAmerican multinational biopharmaceutical company whose dividend yield and payout ratio were compared.
  • Gilead SciencesAmerican company whose dividend yield and payout ratio were compared against Amgen.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • AmgenSpeculative

    Amgen might experience changes in its market price and competitive position based on the comparison of its revenue growth and dividend structure.

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped